Direct versus indirect thrombin inhibition in percutaneous coronary intervention.
Marmur
Jonathan D
JD
Mount Sinai Medical Center, New York, New York, USA.
D015906:Angioplasty, Balloon, Coronary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014914:Whole Blood Coagulation Time
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D019039:Platelet Glycoprotein GPIIb-IIIa Complex